Biophytis S.A. (BPTS)

NASDAQ: BPTS · IEX Real-Time Price · USD
0.660
+0.081 (13.91%)
Oct 4, 2022 11:28 AM EDT - Market open
13.91%
Market Cap 10.74M
Revenue (ttm) n/a
Net Income (ttm) -35.51M
Shares Out 16.27M
EPS (ttm) -2.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 7,701
Open 0.694
Previous Close 0.580
Day's Range 0.660 - 0.694
52-Week Range 0.560 - 8.370
Beta 1.45
Analysts Sell
Price Target 1.43 (+116.6%)
Earnings Date n/a

About BPTS

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in dev... [Read more...]

Industry Biotechnology
IPO Date Feb 10, 2021
CEO Stanislas Veillet
Employees 26
Stock Exchange NASDAQ
Ticker Symbol BPTS
Full Company Profile

Financial Performance

Financial numbers in EUR Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for BPTS stock is "Sell." The 12-month stock price forecast is 1.43, which is an increase of 116.60% from the latest price.

Price Target
$1.43
(116.60% upside)
Analyst Consensus: Sell
Stock Forecasts

News

Biophytis Participates in H.C. Wainwright 24th Annual Global Investment Conference

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 15, 2022 / Biophytis SA (NasdaqCM:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focus...

2 weeks ago - Accesswire

The Paris Court of Appeal Rules in Favour of Biophytis in the Case Against Negma Group Ltd

On July 16th July 2021, the Paris Court had imposed on Biophytis a penalty payment of EUR 1,500,000 in favour of Negma Group Ltd, following a judgment of the Paris Commercial Court On September 8th 2022...

3 weeks ago - Accesswire

Biophytis Announces Very Promising Top Line Results of its Phase 2-3 COVA Clinical Study in COVID-19-Related Respirat...

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 7th, 2022 / Biophytis SA (NasdaqCM:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focu...

3 weeks ago - Accesswire

Biophytis Announces the Drawing of the Second Tranche of Ornane Under the 2021 Atlas Contract for €4 Million

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / June 30, 2022 / Biophytis SA (NasdaqCM:BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeuti...

3 months ago - Accesswire

Biophytis Presents the Development of Sarconeos (BIO101) in Phase 3 for the Treatment of Sarcopenia at the 15th SCWD ...

PARIS, FRANCE and CAMBRIDGE, MASSACHUSETTS / ACCESSWIRE / June 27, 2022 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company ...

3 months ago - Accesswire

Biophytis: Results of the Combined General Meeting on June 21, 2022

All ordinary and extraordinary resolutions presented by the company have been adopted PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / June 22, 2022 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:A...

3 months ago - Accesswire

Biophytis: Convening of Another Combined General Meeting at a Later Date

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / June 3, 2022 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company focused on t...

4 months ago - Accesswire

Biophytis: Biophytis Announces its Participation at the BIO International Convention in San Diego from the 13th to th...

PARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / May 12, 2022 / Biophytis SA (NasdaqCM:BPTS, Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company focused on t...

4 months ago - Accesswire

Biophytis: Biophytis Presents Sarconeos (BIO101) Development Program in Sarcopenia at the 12th Annual International C...

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 19, 2022 / Biophytis SA ((NASDAQ:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company focused o...

5 months ago - Accesswire

Biophytis Shares Fall As It Stops Enrollment In Sarconeos COVID-19 Trial, Data Expected In Q3 2022

Biophytis SA (NASDAQ: BPTS) said that it is currently assessing FDA comments and recommendations and preparing to submit Phase 2-3 trial designs for sarconeos (BIO101) trial in sarcopenia. Enrollment is...

5 months ago - Benzinga

Biophytis Announces 2021 Operational and Financial Results and Gives Updates on 2022 perspectives

Success of Nasdaq IPO in February 2021 €23.9M of available cash on December 31 2021 and new financing instruments for a total of €42M allowing financial visibility beyond mid 2023 Strong growth of opera...

5 months ago - Accesswire

Biophytis Provides Updates on Sarconeos (BIO101) Clinical Development

Sarcopenia (SARA) : discussions engaged with FDA for the preparation of a Phase 2-3 program in sarcopenia, with the objective of having a First Patient In by end of H2 2022 COVID-19 (COVA): 237 patients...

5 months ago - Accesswire

Biophytis Appoints Philippe Rousseau as Chief Financial Officer

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 5, 2022 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company specialized ...

5 months ago - Accesswire

Biophytis will Participate in a Key Workshop on Functional Limitations for the Elderly

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / March 16,2022 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "company") a clinical-stage biotechnology company focused on t...

6 months ago - Accesswire

Why Are Biophytis Shares Trading Higher During Premarket Trading?

Biophytis SA BPTS has received approval from the ANVISA (Brazilian health authority) for its Expanded Access Program (EAP) to treat hospitalized patients with severe COVID-19 with Sarconeos (BIO101).  T...

8 months ago - Benzinga

Biophytis Received Approval from ANVISA (Brazil) to Give Access to Sarconeos (BIO101) to Hospitalized COVID-19 Patien...

ANVISA (Brazilian Health Authority) approved Biophytis' Expanded Access Program (EAP) for hospitalized patients with severe COVID-19 and mechanically ventilated in Intensive Care Unit Sarconeos (BIO101)...

8 months ago - Accesswire

Biophytis Announces the Drawing of the Last Tranche of ORNANE Under the 2020 Atlas Contract for €3 Million

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / December 22, 2021 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS), a clinical-stage biotechnology company focused on the development of therapeut...

9 months ago - Accesswire

Biophytis to Meet with FDA to Advance Sarconeos (BIO101) Development in Sarcopenia from Phase 2 to Phase 3

Following Phase2b/SARA-INT clinically meaningful results, Biophytis is starting first regulatory activities to advance from Phase 2 to Phase 3 development A Type B/End-of-Phase 2 meeting is planned with...

9 months ago - Accesswire

Biophytis Obtains a New 10M€ Loan Structure With Kreos Capital

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / November 22, 2021 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris: ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused...

10 months ago - Accesswire

Biophytis To Restart Recruitment In US Centers For COVID-19 Trial

Biophytis SA (NASDAQ: BPTS) has announced that patient recruitment in the U.S., paused in May while waiting for results of the Interim Analysis 2, has restarted.  The Data Monitoring Committee (DMC) had...

10 months ago - Benzinga

Biophytis Announces US Centers to Restart Recruitment for the COVA Phase 2-3 Study with Sarconeos (BIO101) in COVID-19

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / November 15, 2021 / Biophytis SA (NasdaqCM:BPTS, Euronext Growth Paris: ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focus...

10 months ago - Accesswire

Biophytis to Report Restated Financial Statements for Previous Periods and as of June 30, 2021

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / October 29, 2021 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused o...

11 months ago - Accesswire

Biophytis to Restate Previously Issued Financial Statements

PARIS and CAMBRIDGE, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS) (the “Company” or “Biophytis”), a clinical-stage biotechnology company focused o...

11 months ago - GlobeNewsWire

Biophytis to Host Virtual KOL Event on Sarconeos (BIO101) on its Lead Projects in COVID-19 and Sarcopenia

PARIS and CAMBRIDGE, Mass., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeuti...

11 months ago - GlobeNewsWire

Biophytis Announces the Drawing of 2 New Tranches of ORNANE Under the 2020 Atlas Contract for €6 Million

PARIS and CAMBRIDGE, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Biophytis SA (NasdaqCM: BPTS, Euronext Growth Paris: ALBPS), a clinical-stage biotechnology company focused on the development of therapeuti...

11 months ago - GlobeNewsWire